On July 22, 2026, MISTR — the LGBTQ+-focused telehealth platform best known for free online PrEP, DoxyPEP, STI testing, and long-term HIV care — announced the launch of erectile-dysfunction medications, headlined by a new flagship product called MISTR Magic. According to the company's GlobeNewswire announcement, MISTR Magic is a single fast-acting dissolvable lozenge that combines sildenafil (the generic form of Viagra) and tadalafil (the generic form of Cialis) into one dose, alongside standalone generic sildenafil and tadalafil options. All are prescribed online with discreet home delivery.

Why It Matters

MISTR's move is a notable example of a sexual-health telehealth platform expanding from disease prevention into pleasure and performance — segments that have historically been served by separate companies (Hims/Ro for ED, MISTR/Nurx for PrEP). By bundling both under one LGBTQ+-native brand, MISTR is testing whether identity-focused platforms can out-compete the mass-market telehealth giants on trust and price within a specific community. For the broader industry, the launch reinforces two 2026 throughlines: relentless price competition on commoditized ED generics, and a race toward novel, discreet delivery formats (films, lozenges, gums, sprays) as the real battleground now that the molecules themselves are cheap. It also underscores how the compounded/telehealth ED channel keeps widening even as the same channel draws regulatory heat in the GLP-1 and testosterone fights.

"Sexual health and sexual confidence go hand in hand. You want to know you've taken the right steps to protect yourself, and you want to be ready when opportunity knocks," founder and CEO Tristan Schukraft said in the announcement, framing the ED line as an "upgrade" rather than a "fix." MISTR pitched the pricing aggressively, claiming its ED options average 49% less than other leading online ED providers — a direct shot across the bow of Hims and Ro, which have built their brands on the same generics.

The strategic logic is that MISTR already has a large, engaged base of gay and bisexual men managing their sexual health on the platform for HIV prevention and treatment; adding ED meds lets it cross-sell confidence products to an audience it has already earned trust with. Schukraft — who has been building an LGBTQ+ lifestyle and health empire that spans MISTR, media, and even Puerto Rico real estate — is betting that "sexual health, fully loaded" resonates with users who want prevention and performance handled in one discreet subscription.

The dissolvable-combo format also rides a clear 2026 product trend. It arrives the same year the FDA approved VYBRIQUE, the first sildenafil oral film, and as Aspargo, Vigo MD, and LTR Pharma all chase novel ED delivery formats (films, gums, nasal sprays, lozenges) to differentiate in a category where the active ingredients are long off-patent. Combining two PDE5 inhibitors in one dose is unusual and will draw clinical scrutiny — sildenafil is short-acting while tadalafil lasts far longer, and stacking them raises questions about dosing, hypotension risk, and nitrate interactions that MISTR's telehealth prescribers will need to manage carefully.

Sources

Update — 2026-07-23

Initial entry — story first created.

Update — 2026-08-23

A month after the July launch, MISTR founder and CEO Tristan Schukraft laid out the strategic reasoning behind the ED expansion in an August 20, 2026 interview with Out magazine, published as part of the title's Sept–Oct 2026 print issue. The interview reframes the product line less as a pricing play against Hims and Ro and more as a deliberate destigmatization campaign aimed at queer men.

Schukraft explicitly maps ED medication onto PrEP's own adoption curve: "Ten years ago, people whispered about it. They called people 'Truvada whores,' and there was real stigma around taking PrEP. Today, friends recommend it to each other, because it's become part of taking care of your health. I think ED medication is on the same path." Citing studies indicating roughly 52 percent of people with penises report some level of ED, he pushes to decouple the category from dysfunction entirely — "For many people, it's not about fixing something that's broken. It's about confidence" — and notes the inconsistency that "gay men will openly compare skincare routines, workouts, and injectables, but when it comes to ED, people suddenly get quiet."

He also restates the portfolio logic driving the expansion — "sexual health doesn't begin and end with preventing HIV or STIs" — and the bundling thesis that distinguishes MISTR from single-product ED sellers: "we don't see ED medication as a standalone product. It's part of a complete sexual health toolkit." The three-option menu (standalone sildenafil, standalone tadalafil, and the compounded MISTR Magic lozenge) is unchanged from launch.

The notable shift since July is positioning rather than product. MISTR is no longer competing primarily on the 49%-cheaper claim; it is competing on being the platform that already holds the patient relationship, which is a far more durable moat in a category where the molecules are commodity generics and customer acquisition cost is the binding constraint.

New Sources